These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15832497)

  • 1. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.
    Kline T; Torgov MY; Mendelsohn BA; Cerveny CG; Senter PD
    Mol Pharm; 2004 Jan; 1(1):9-22. PubMed ID: 15832497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
    Albright CF; Graciani N; Han W; Yue E; Stein R; Lai Z; Diamond M; Dowling R; Grimminger L; Zhang SY; Behrens D; Musselman A; Bruckner R; Zhang M; Jiang X; Hu D; Higley A; Dimeo S; Rafalski M; Mandlekar S; Car B; Yeleswaram S; Stern A; Copeland RA; Combs A; Seitz SP; Trainor GL; Taub R; Huang P; Oliff A
    Mol Cancer Ther; 2005 May; 4(5):751-60. PubMed ID: 15897239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
    Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
    Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
    Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
    Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.
    Kratz F; Drevs J; Bing G; Stockmar C; Scheuermann K; Lazar P; Unger C
    Bioorg Med Chem Lett; 2001 Aug; 11(15):2001-6. PubMed ID: 11454467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
    Akinboye ES; Rosen MD; Bakare O; Denmeade SR
    Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.
    Zhang J; Li X; Jiang Y; Feng J; Li X; Zhang Y; Xu W
    Bioorg Med Chem; 2014 Jun; 22(11):3055-64. PubMed ID: 24755524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
    Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
    Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells.
    Bakar F; Kilic-Kurt Z; Caglayan MG; Olgen S
    Anticancer Agents Med Chem; 2017; 17(5):762-767. PubMed ID: 27491936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates.
    Lauer-Fields JL; Broder T; Sritharan T; Chung L; Nagase H; Fields GB
    Biochemistry; 2001 May; 40(19):5795-803. PubMed ID: 11341845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
    Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
    Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX.
    Chau Y; Tan FE; Langer R
    Bioconjug Chem; 2004; 15(4):931-41. PubMed ID: 15264885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase.
    Spallarossa P; Altieri P; Garibaldi S; Ghigliotti G; Barisione C; Manca V; Fabbi P; Ballestrero A; Brunelli C; Barsotti A
    Cardiovasc Res; 2006 Feb; 69(3):736-45. PubMed ID: 16213474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP-2 selectivity in hydroxamate-type inhibitors.
    Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
    Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma.
    Klisovic DD; Klisovic MI; Effron D; Liu S; Marcucci G; Katz SE
    Melanoma Res; 2005 Jun; 15(3):147-53. PubMed ID: 15917695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
    Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
    J Med Chem; 1983 May; 26(5):638-44. PubMed ID: 6302253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.